Stocks and Investing Stocks and Investing
Fri, May 4, 2018

Alethia Young Maintained (SRPT) at Buy with Decreased Target to $92 on, May 4th, 2018


Published on 2024-10-26 05:22:10 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $100 to $92 on, May 4th, 2018.

Alethia has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Alethia


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018
  • Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018

Contributing Sources